Utah monthly communicable disease report
February 2024
Background: The Utah Department of Health and Human Services collects data on over 75 communicable diseases that affect the residents of Utah. These data are monitored by epidemiologists to detect changes in disease activity and guide prevention and education efforts. More information can be found here.
Note: Individual disease investigations take time to complete; for this reason, data in this report should be considered provisional and will change as more complete reports are received.
| Feb 2024 | 5-yr Feb avg* | 2024 YTD‡ | 5-yr YTD avg*‡ | |
|---|---|---|---|---|
| Acute Flaccid Myelitis | 0 | U | 0 | U |
| Adverse event resulting from smallpox vaccination | 0 | 0 | 0 | 0 |
| Amebiasis | 0 | 0 | 0 | 0 |
| Anthrax | 0 | 0 | 0 | 0 |
| Arbovirus infection (not including West Nile, Dengue, or Yellow Fever) | 0 | 0 | 0 | 0 |
| Babesiosis | 0 | 0 | 0 | 0 |
| Botulism, total | 0 | 0 | 0 | 0.4 |
| Botulism, foodborne | 0 | 0 | 0 | 0.2 |
| Botulism, infant | 0 | 0 | 0 | 0.2 |
| Botulism, other (wound/unspecified) | 0 | 0 | 0 | 0 |
| Brucellosis | 0 | 0.2 | 0 | 0.4 |
| Campylobacteriosis | 50 | 35 | 105 | 75.2 |
| Chancroid | 0 | 0 | 0 | 0 |
| Chickenpox | 15 | 8.2 | 31 | 21.4 |
| Chlamydia | 886 | 864.8 | 1752 | 1826.6 |
| Cholera | 0 | 0 | 0 | 0 |
| Coccidioidomycosis | 7 | 3.4 | 24 | 7.2 |
| Colorado tick fever | 0 | 0 | 0 | 0 |
| COVID-19 | 2838 | *** | 8106 | *** |
| Creutzfeldt-Jakob disease and other transmissible human spongiform encephalopathies | 0 | 0.4 | 0 | 0.4 |
| Cryptosporidiosis | 9 | 9.2 | 24 | 21.8 |
| Cyclosporiasis | 0 | 0.2 | 0 | 0.2 |
| Dengue | 0 | 0.2 | 2 | 0.2 |
| Diphtheria | 0 | U | 0 | U |
| Echinococcosis | 0 | 0 | 0 | 0 |
| Ehrlichiosis/Anaplasmosis | 0 | 0 | 0 | 0 |
| Encephalitis | 0 | 0.2 | 0 | 0.2 |
| Giardiasis | 12 | 11 | 33 | 23.2 |
| Gonorrhea | 154 | 231.8 | 327 | 489.2 |
| HIV infection | 16 | 11 | 31 | 20 |
| Haemophilus influenzae, all ages, invasive disease | 6 | 3.6 | 14 | 8 |
| nonserotype B, age <5 years | 0 | 0.4 | 0 | 1.2 |
| serotype B, age <5 years | 0 | 0 | 0 | 0 |
| unknown serotype, age <5 years | 0 | 0 | 0 | 0 |
| Hansen’s disease (Leprosy) | 0 | 0 | 0 | 0.2 |
| Hantavirus infection | 0 | 0 | 0 | 0 |
| Hemolytic uremic syndrome, post-diarrheal | 1 | 0.4 | 1 | 0.6 |
| Hepatitis A | 0 | 1.2 | 0 | 2.2 |
| Hepatitis B, acute | 0 | 1 | 2 | 2.6 |
| Hepatitis B, chronic | 5 | 4.6 | 13 | 9.4 |
| Hepatitis C, acutea | 10 | 17 | 18 | 33.8 |
| Hepatitis C, chronicb | 94 | 102.6 | 199 | 219.6 |
| Hepatitis, other viral | 0 | 0 | 0 | 0 |
| Influenza-associated hospitalization | 213 | 245.6 | 738 | 492.6 |
| Influenza-associated pediatric mortality | 1 | 0.6 | 1 | 1 |
| Legionellosis | 3 | 1.4 | 4 | 3 |
| Leptospirosis | 1 | 0 | 1 | 0 |
| Listeriosis | 1 | U | 1 | U |
| Lyme disease | 0 | 0.4 | 2 | 1.4 |
| Malaria | 0 | 0.4 | 1 | 1.8 |
| Measles | 0 | 0 | 0 | 0 |
| Meningitis, aseptic | 0 | 0.4 | 0 | 0.8 |
| Meningitis, bacterial, other | 0 | 1.8 | 0 | 3.6 |
| Meningitis, viral | 0 | 1.2 | 0 | 2.4 |
| Meningococcal Disease (Neisseria meningitidis) | 0 | 0 | 0 | 0.2 |
| Mumps | 0 | 0.6 | 0 | 1.6 |
| Pertussis | 13 | 17.2 | 28 | 37.2 |
| Plaguec | 0 | 0 | 0 | 0 |
| Poliomyelitis, paralytic and nonparalytic | 0 | 0 | 0 | 0 |
| Psittacosis | 0 | 0 | 0 | 0 |
| Q fever | 0 | 1 | 0 | 1.2 |
| Rabies, animal | 0 | 0 | 0 | 0 |
| Rabies, human | 0 | 0 | 0 | 0 |
| Relapsing fever, tick-borne and louse-borne | 0 | 0 | 0 | 0 |
| Rubella | 0 | 0 | 0 | 0 |
| Rubella, congenital syndrome | 0 | 0 | 0 | 0 |
| Salmonellosis | 25 | 13.6 | 55 | 33.8 |
| Severe Acute Respiratory Syndrome (SARS) | 0 | 0 | 0 | 0 |
| Shiga toxin-producing Escherichia coli (STEC) infection | 16 | 14.2 | 23 | 23.6 |
| Shigellosis | 10 | 5.6 | 21 | 13.8 |
| Smallpox | 0 | 0 | 0 | 0 |
| Spotted fever rickettsiosis (including Rocky Mountain Spotted Fever) | 0 | 0 | 0 | 0.2 |
| Streptococcal disease, invasive, group A | 24 | 25.6 | 62 | 52.2 |
| Streptococcal disease, invasive, group B | 18 | 17.4 | 37 | 38.4 |
| Streptococcal disease, invasive, other | 4 | 38 | 4 | 72.8 |
| Streptococcus pneumoniae, invasive disease | 24 | 21.8 | 45 | 40.8 |
| age <5 years | 4 | 1.6 | 6 | 2.6 |
| Syphilis, congenital | 0 | 0 | 0 | 0 |
| Syphilis, early (infection < 12 months) | 19 | 13.6 | 45 | 29.2 |
| primary & secondary | 19 | 13.6 | 45 | 29.2 |
| early latent | 0 | 0 | 0 | 0 |
| Syphilis, latent (infection > 12 months) | 0 | 0 | 0 | 0 |
| Tetanus | 0 | 0 | 0 | 0 |
| Toxic shock syndrome (staphylococcal or streptococcal) | 4 | 3.8 | 6 | 7 |
| Trichinellosis | 0 | 0 | 0 | 0 |
| Tuberculosis, active | 5 | 2.2 | 8 | 4.4 |
| Tularemia | 0 | 0.2 | 0 | 0.2 |
| Typhoid fever | 0 | 0 | 0 | 0 |
| Vancomycin-intermediate Staphylococcus aureus (VISA) | 0 | 0 | 0 | 0 |
| Vancomycin-resistant Staphylococcus aureus (VRSA) | 0 | 0 | 0 | 0 |
| Vibriosis | 0 | 0.4 | 5 | 1 |
| Viral hemorrhagic fevers | 0 | 0 | 0 | 0 |
| West Nile virus, total | 0 | 0 | 0 | 0 |
| Yellow fever | 0 | 0 | 0 | 0 |
| Zika Virus Disease | 0 | U | 0 | U |
| Note: | ||||
| U: 5-yr average is unavailable (U) because of changes in communicable disease reporting rules. | ||||
| a In 2019, the DHHS began reporting only confirmed cases of acute Hepatitis C. Previously, the DHHS reported confirmed and probable cases. The 5 year averages presented here represent only confirmed cases in the past 5 years. | ||||
| b In 2019, the DHHS began reporting only confirmed cases of chronic Hepatitis C. Previously, the DHHS reported confirmed and probable cases. The 5 year averages presented here represent only confirmed cases in the past 5 years. | ||||
| c In 2019, the DHHS began reporting only confirmed cases of plague. Previously, the DHHS reported confirmed and probable cases. The 5 year averages presented here represent only confirmed cases in the past 5 years. | ||||
| * Averages are susceptible to skewing due to outbreaks and should be interpreted with care. | ||||
| † YTD indicates counts are year-to-date. |